- Home
- RERE vs PRTC Comparison
RERE vs PRTC Comparison
Compare RERE & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- PRTC
- Stock Information
- Founded
- RERE 2011
- PRTC 2015
- Country
- RERE China
- PRTC United States
- Employees
- RERE N/A
- PRTC N/A
- Industry
- RERE Other Specialty Stores
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- PRTC Health Care
- Exchange
- RERE Nasdaq
- PRTC Nasdaq
- Market Cap
- RERE 444.1M
- PRTC 439.8M
- IPO Year
- RERE 2021
- PRTC N/A
- Fundamental
- Price
- RERE $2.90
- PRTC $17.90
- Analyst Decision
- RERE
- PRTC Buy
- Analyst Count
- RERE 0
- PRTC 1
- Target Price
- RERE N/A
- PRTC $45.00
- AVG Volume (30 Days)
- RERE 759.2K
- PRTC 2.0K
- Earning Date
- RERE 08-19-2025
- PRTC 04-30-2025
- Dividend Yield
- RERE N/A
- PRTC N/A
- EPS Growth
- RERE N/A
- PRTC N/A
- EPS
- RERE 0.07
- PRTC 0.21
- Revenue
- RERE $2,388,301,386.00
- PRTC $4,828,000.00
- Revenue This Year
- RERE $27.37
- PRTC $35.98
- Revenue Next Year
- RERE $24.06
- PRTC $115.38
- P/E Ratio
- RERE $40.03
- PRTC $7.81
- Revenue Growth
- RERE 26.09
- PRTC 44.98
- 52 Week Low
- RERE $2.00
- PRTC $13.30
- 52 Week High
- RERE $3.70
- PRTC $28.39
- Technical
- Relative Strength Index (RSI)
- RERE 63.02
- PRTC 46.07
- Support Level
- RERE $2.64
- PRTC $19.00
- Resistance Level
- RERE $2.89
- PRTC $19.80
- Average True Range (ATR)
- RERE 0.14
- PRTC 0.33
- MACD
- RERE 0.03
- PRTC -0.12
- Stochastic Oscillator
- RERE 73.13
- PRTC 16.30
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.